Cargando…
P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431015/ http://dx.doi.org/10.1097/01.HS9.0000970604.12677.40 |
| _version_ | 1785091098529497088 |
|---|---|
| author | Chen, Wenming Huang, Zhongxia Fang, Baijun Song, Yuqin Jing, Hongmei Xia, Zhongjun Cai, Zhen An, Gang Zhou, Huixing Liu, Nian LI, Xin Liu, Yuzhang Ping, Lingyan Wan, Wei Chen, Xiaoqin He, Jingsong Xu, Yan |
| author_facet | Chen, Wenming Huang, Zhongxia Fang, Baijun Song, Yuqin Jing, Hongmei Xia, Zhongjun Cai, Zhen An, Gang Zhou, Huixing Liu, Nian LI, Xin Liu, Yuzhang Ping, Lingyan Wan, Wei Chen, Xiaoqin He, Jingsong Xu, Yan |
| author_sort | Chen, Wenming |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431015 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310152023-08-17 P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA Chen, Wenming Huang, Zhongxia Fang, Baijun Song, Yuqin Jing, Hongmei Xia, Zhongjun Cai, Zhen An, Gang Zhou, Huixing Liu, Nian LI, Xin Liu, Yuzhang Ping, Lingyan Wan, Wei Chen, Xiaoqin He, Jingsong Xu, Yan Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431015/ http://dx.doi.org/10.1097/01.HS9.0000970604.12677.40 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Chen, Wenming Huang, Zhongxia Fang, Baijun Song, Yuqin Jing, Hongmei Xia, Zhongjun Cai, Zhen An, Gang Zhou, Huixing Liu, Nian LI, Xin Liu, Yuzhang Ping, Lingyan Wan, Wei Chen, Xiaoqin He, Jingsong Xu, Yan P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title | P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title_full | P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title_fullStr | P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title_full_unstemmed | P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title_short | P925: PHASE 1 TRIAL OF ANTI-CD38 MONOCLONAL ANTIBODY CM313 IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR LYMPHOMA |
| title_sort | p925: phase 1 trial of anti-cd38 monoclonal antibody cm313 in patients with relapsed/refractory multiple myeloma or lymphoma |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431015/ http://dx.doi.org/10.1097/01.HS9.0000970604.12677.40 |
| work_keys_str_mv | AT chenwenming p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT huangzhongxia p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT fangbaijun p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT songyuqin p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT jinghongmei p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT xiazhongjun p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT caizhen p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT angang p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT zhouhuixing p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT liunian p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT lixin p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT liuyuzhang p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT pinglingyan p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT wanwei p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT chenxiaoqin p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT hejingsong p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma AT xuyan p925phase1trialofanticd38monoclonalantibodycm313inpatientswithrelapsedrefractorymultiplemyelomaorlymphoma |